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Response to MEK inhibition with trametinib and 
tyrosine kinase inhibition with imatinib in multifocal
histiocytic sarcoma
In December 2015, a 66-year-old man was referred to
our university hospital with a recent diagnosis of histio-
cytic sarcoma. The patient had presented recurrent
abdominal pain for two months without B symptoms.
CT scan evidenced an ileal mass, multiple hepatic lesions,
and diffuse abdominal and mediastinal adenopathies.
Coronal section of PET-CT is shown in Figure 1A. After
two liver biopsies, that were initially not conclusive, and
a negative bone marrow biopsy, a surgical resection of
the terminal ileum was performed, showing a transmural
tumor interpreted as histiocytic sarcoma.
Histopathological review confirmed an infiltrate of large,
pleomorphic and atypical histiocytoid cells with abun-
dant cytoplasm (Figure 2). Immunohistochemistry
showed that the cells were CD3–, CD68+, CD163+, HLA-
DR+, muramidase (lysozyme)+/-, S100-/+, CD1a– and lan-
gerin-. Ki67 proliferation fraction was heterogeneous, but
overall low (about 10%). No mutations were detected in
BRAF exon 15 and 11, while fluorescence in situ
hybridization (FISH) study demonstrated the absence of
PDGFRA, PDGFRB, and FGFR1 rearrangements but a
copy number gain (mostly 2-5 fold, but up to 9 fold) in
the 3 studied loci. PDL-1 expression was heterogeneous
in 15-20% of the tumour cells. Retrospectively, the two
liver biopsies were revised and tested positive for the
same pathology with presence of an important T-cell
reactive population. 
An allogeneic hematopoietic stem cell transplantation
(HSCT) was considered indicated, but only after at least
a good response of the tumor burden. The patient was
initially treated with 2 cycles of CHOP therapy
(cyclophosphamide, 750 mg/m2 i.v. on day 1; doxoru-
bicin, 50 mg/m2 i.v. on day 1; vincristine, 1.4 mg/m2 i.v.
on day 1, and prednisone, 100 mg p.o. on day 1 through
5 every 21 days). A mixed response was observed on the
PET-scan. Two hepatic lesions and mediastinal, subclav-
icular and abdominal adenopathies disappeared, while
other sites (lung, liver, gut and femur) showed progres-
sion with new lesions. A salvage therapy with ICE (ifos-
famide 5000 mg/m2 i.v. fractionated into three equally
divided doses over 3 days, carboplatin [mg dose = 5 ×
area under the curve (AUC)] i.v. on day 1 and etoposide
100 mg/m2 i.v. daily for 3 consecutive days, every 21
days) was conducted for 2 cycles. Again, PET-CT (figure
1B) showed a mixed response with progressive disease in
the liver, stability in the bone, and response in all
adenopathies and in the lung lesion. A liver biopsy was
performed and showed involvement by histiocytic sarco-
ma with no evidence of necrosis.  A third-line therapy
with alemtuzumab (30 mg subcutaneous three times a
week) was initiated, but the PET-CT showed progressive
disease after two months (figure 1C).
After failure of these three treatment lines, the initial
ileal resection piece was further analyzed by NGS (Next
Generation Sequencing) using a panel of 52 genes (Ion
AmpliSeqTM) covering 218 hotspot regions in search of
potentially targetable genomic alterations. This analysis
revealed the presence of a potential oncogenic mutation
c.226G>A (p.E72K) in the PTPN11 gene, exon 3 (allele
frequency 29.2%) as well as a one-copy gain of STK11,
GNA11 and JAK3 loci (19p13).
The patient was discussed at our institutional molecu-
lar tumor-board. PTPN11 encodes for SHP2, which is a
negative regulator of the Ras/MAPK pathway. Mutations
in PTPN11, for example in Noonan syndrome, result in
activated MAPK signaling.1 GNA11, is a G protein cou-
pled receptor and also activates the MAPK pathway.
Based on the PTPN11 mutation and copy number gain of
GNA11, a hyperactivation of the MAPK pathway was
predicted. The patient was treated with the MEK
inhibitor trametinib 2 mg daily to block the RAS/MAPK
pathway. Excellent partial remission was observed after 2
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Figure 1. PET-CT scan. A: initial coronal section. B: after conventional chemotherapy (CHOP and ICE). C: after alemtuzumab, and D:  after two months of treat-
ment with trametinib.
months of treatment: only 2 lymph nodes and 1 small
pulmonary lesion persisted, with clear diminution of the
size and hypermetabolic capture (Figure 1D).
Unfortunately, the patient suffered from several adverse
events while on trametinib treatment: he developed a
grade 3 acneiform rash and a grade 3 QTc interval prolon-
gation on ECG requiring dose reduction and several treat-
ment interruptions. Throughout the five months of tram-
etinib treatment, he received 10 days at 2 mg, 21 days at
1.5 mg, and 46 days at 1 mg. Despite very low dose med-
ication, the excellent response described above persisted
until progressive disease was documented on PET-CT
scan five months after trametinib initiation, while still on
treatment (lymph nodes, lung, liver and bone). 
Due to the copy number gain of PDGFRA and PDGFRB
in FISH analysis, the patient was subsequently treated
with imatinib (400 mg daily for 4 weeks followed by 800
mg daily) as next clinical option. We performed NGS for
52 genes and PDGFRA and PDGFRB FISH almost simul-
taneously. Since the NGS found both a PTPN11 mutation
and gain of copies of GNA11 but did not confirm the
FISH gain of copies results of PDGFRA, we considered
the NGS as higher level of evidence than the FISH analy-
sis alone, hence our first choice was trametinib.
Three months after imatinib introduction, a mixed
response could again be demonstrated on PET-scan with
partial response on the supra-diaphragmatic lymph
nodes, complete disappearance of the liver lesions, but
increased gut and lung FDG-uptake, as well as progres-
sive abdominal lymph nodes, together with a dissociated
response in bone infiltrates. The patient was still in good
performance status (ECOG 1) without specific com-
plaints apart from grade 1 fatigue. Currently, the patient
has been initiated on another experimental treatment
line by checkpoint inhibitor anti-PD1 nivolumab.
Histiocytic sarcoma is an extremely rare malignant dis-
ease that has an aggressive clinical course with a dismal
outcome, most patients dying within 2 years after diag-
nosis.2,3 Currently, no standard treatment approach is
defined due to the low frequency of the disease and  con-
sequent lack of clinical studies. Despite absence of
prospective clinical data, non-Hodgkin lymphoma treat-
ment approaches are often used for multifocal disease,
but results are rather disappointing.4 Few data exist for
autologous and even less for allogeneic stem cell trans-
plantation in the adult population, but some patients
have shown favorable outcomes.2,5,6 Thalidomide and
alemtuzumab have been reported as potential therapies
in single case reports, both in the pediatric or transplant
setting.6-10 Furthermore, since BRAF mutations (V600E,
G464V and others)11,12 are frequently detected in histio-
cytic sarcoma, vemurafenib, dabrafenib and trametinib
haematologica 2018; 103:e40
CASE REPORTS
Figure 2. Pathology of the tumor. (A) low magnification showing diffuse involvement of the intestinal wall (mucosa at the top) (hematoxylin and eosin, original
magnification x40); (B) high magnification of the tumor composed of large cells with vesicular to hyper chromatic nuclei and abundant eosinophilic cytoplasm




are potential targeted drugs for patients in which one of
these mutations has been detected. These studies did not
demonstrate an influence of the BRAF mutational status
on the natural course of the disease. Whether the treat-
ment with targeted drugs can influence the outcome
remains to be determined. Also, PD-L1 overexpression
and PTEN mutations have been described and can be tar-
geted nowadays.13 However, as the disease is very rare,
no clinical data of larger studies are available to date.
In our patient, we identified two alterations suggestive
of MAPK activation: 1, a mutation in the PTPN11 gene
and 2, a 3-fold copy gain of GNA11. MEK inhibitors, like
trametinib or cobimetinib can efficiently block the
MAPK. To our knowledge, this is the first case described
to date with a documented response of a histiocytic sar-
coma to trametinib, with another case associated with
follicular lymphoma where MAPK2K1 mutation and
response to MEK inhibition was documented.14
Unfortunately, due to adverse events of grade 3, the
treatment had to be dose-adjusted and then definitely
interrupted after five months.
Interestingly, tyrosine kinase inhibition with imatinib
following trametinib discontinuation, also resulted in a
documented response. 
In conclusion, this case reports an excellent response to
targeted MEK inhibition in a histiocytic sarcoma. Targeting
the RAF/RAS/MEK pathway may be a promising thera-
peutic option in such patients with an otherwise dismal
outcome. We could furthermore demonstrate a potential
for Imatinib in the treatment of this rare disease. Further
and larger clinical studies are needed, evaluating treatment
responses in bigger cohorts in a controlled setting.
Combining these targeted therapies could be a future
treatment possibility; however, increased toxicities may be
a concern. The possibility of better molecular characterisa-
tion of rare diseases raises hope for targeted therapy
options in difficult to treat diseases. However, it will be
difficult to obtain clinical trial data with statistical impact
for all the different targeted treatment options, more so if
treatment combinations are being tested.
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